930. Deputy George Lawlor asked the Minister for Health if she will intervene to ensure that the belzutafan which was approved by the European Medicines Agency in December 2024 for treatment of the genetic condition Von Hippel Lindau (VHL) is made available to patients in this country; the number of persons with this condition who could benefit from this new treatment; and if she will make a statement on the matter. …
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
940. Deputy Michael Collins asked the Minister for Health the reason the HSE has not yet approved funding for the drug dupixent (dupilumab) for adults with eosinophilic oesophagitis; the stage the pricing and assessment process is currently at; when a decision is expected; and if she will make a statement on the matter. [45320/26]
941. Deputy Michael Collins asked the Minister for Health the supports available for patients with eosinophilic oesophagitis who cannot access standard treatments such as jorveza; whether the HSE will provide urgent access to dupixent through the individual patient approval scheme in serious cases; and if she will make a statement on the matter. [45321/26]
946. Deputy Pearse Doherty asked the Minister for Health when a person will get an appointment for pain management injections (details supplied); and if she will make a statement on the matter. [45382/26]
947. Deputy Ann Graves asked the Minister for Health if she will give a commitment to expedite the approval of givinostat here (details supplied). [45399/26]
949. Deputy Mark Ward asked the Minister for Health the reason the State is not pursuing fair pricing on an EU-wide basis regarding the topic of givinostat therapy for Duchenne muscular dystrophy; the reason this is only being considered in the context of the Irish market; if precedence for EU-wide negotiation has been used for drug pricing; and if she will make a statement on the matter. [45404/26]
959. Deputy Naoise Ó Muirí asked the Minister for Health the frequency with which the HSE PCRS will make a pharmacy liable for the difference between the reference price and reimbursement price of ‘Do Not Substitute’ drugs; the number of claim investigations by the PCRS in 2026; and if she will make a statement on the matter. [45561/26]
966. Deputy John Paul O'Shea asked the Minister for Health the current status of the reimbursement application for givinostat for the treatment of Duchenne muscular dystrophy; the timeline for consideration of the drug by the HSE Drugs Group and subsequent decision-making processes; the measures being taken to ensure that, should reimbursement be approved, access can be provided to eligible patients without unnecessa…
978. Deputy Thomas Gould asked the Minister for Health the plans to approve the weight loss medications ozempic and mounjaro for inclusion in the drugs payment scheme; and if she will make a statement on the matter. [45657/26]
1000. Deputy Brian Stanley asked the Minister for Health if a medication (details supplied) is a reimbursable medication under the drugs payment scheme; the qualifying criteria a patient must meet in order to be approved for reimbursement of this medication; and if she will make a statement on the matter. [45780/26]
1008. Deputy Mark Wall asked the Minister for Health when she expects the HSE to confirm urgent access to givinostat for boys living with Duchenne muscular dystrophy; and if she will make a statement on the matter. [45878/26]
1017. Deputy Pádraig Rice asked the Minister for Health to provide an update on the position regarding a drug for people living with Duchenne muscular dystrophy (details supplied); the outcome of the HSE Drug’s Group meeting on 10 June 2026; and if she will make a statement on the matter. [45899/26]
1030. Deputy Louis O'Hara asked the Minister for Health the steps her Department is taking to provide access to givinostat; and if she will make a statement on the matter. [45947/26]
314. Deputy Naoise Ó Cearúil asked the Minister for Health the status of the reimbursement process for givinostat for the treatment of Duchenne muscular dystrophy; the timeline for a decision following consideration by the HSE Drugs Group; the steps being taken to ensure timely access for eligible patients once a decision is made; and if she will make a statement on the matter. [44665/26]
343. Deputy Michael Cahill asked the Minister for Health to clarify the position in relation to blister packs, including any associated costs; and if she will make a statement on the matter. [44783/26]
347. Deputy Cathal Crowe asked the Minister for Health the status of price negotiations between the Health Service Executive Corporate Pharmaceutical Unit and the manufacturer regarding the reimbursement of omaveloxolone (skyclarys) for the treatment of Friedreich's ataxia; if she will address concerns regarding the omission of this life-altering therapy from the immediate agenda of the HSE Drugs Group ahead of the s…
349. Deputy Cathal Crowe asked the Minister for Health the status of the reimbursement process for the medication givinostat (duvyzat) for patients living with Duchenne muscular dystrophy (DMD); if she will provide an update on the outcome of the HSE Drugs Group meeting scheduled for 10 June 2026; the timeline for a final decision by the HSE leadership; if she will ensure that the clinical eligibility criteria will b…
350. Deputy Michael Cahill asked the Minister for Health to ensure that all children within the State receive urgent access to givinostat (duvyzat) for Duchenne muscular dystrophy (details supplied); and if she will make a statement on the matter. [44837/26]
355. Deputy Michael Healy-Rae asked the Minister for Health to review medication on the drugs payment scheme for a person (details supplied); and if she will make a statement on the matter. [44849/26]
356. Deputy Colm Burke asked the Minister for Health when the HSE will make a decision on reimbursement for the drug givinostat for patients with Duchenne muscular dystrophy; and if she will make a statement on the matter. [44850/26]
357. Deputy Colm Burke asked the Minister for Health to provide an update on the availability of the drug givinostat for patients with Duchenne muscular dystrophy; and if she will make a statement on the matter. [44851/26]
360. Deputy Michael Cahill asked the Minister for Health to ensure that all children within the State receive urgent access to givinostat (duvyzat) for Duchenne muscular dystrophy (details supplied); and if she will make a statement on the matter. [44860/26]
361. Deputy Michael Cahill asked the Minister for Health to ensure that all children within the State receive urgent access to givinostat (duvyzat) for Duchenne muscular dystrophy (details supplied); and if she will make a statement on the matter. [44861/26]
362. Deputy Michael Cahill asked the Minister for Health to ensure that all children within the State receive urgent access to givinostat (duvyzat) for Duchenne muscular dystrophy (details supplied); and if she will make a statement on the matter. [44863/26]
363. Deputy Paula Butterly asked the Minister for Health the steps being taken to expedite access and reimbursement for givinostat for children living with Duchenne muscular dystrophy here (details supplied) [44870/26]